MedTrace Logo

Voriconazole for IPA in Chinese Patients With COPD

NCT02234739 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2014-09-09

No results posted yet for this study

Summary

voriconazole is recommended as first-line therapy for invasive pulmonary aspergillosis, however the efficacy and safety of voriconazole for treating invasive pulmonary aspergillosis secondary to COPD is not clear. This study aims to investigate the effectiveness and tolerability of intravenous voriconazole for treatment of invasive pulmonary aspergillosis in Chinese patients with COPD, by monitoring changes in clinical symptoms, eradication of aspergillus, improvement of chest imaging as well as record of possible adverse reactions following 2-week intravenous instillation of voriconazole.

Conditions

  • Invasive Pulmonary Aspergillosis
  • COPD

Interventions

DRUG

Voriconazole

2-week long intravenous instillation of voriconazole

Sponsors & Collaborators

  • Sir Run Run Shaw Hospital

    collaborator OTHER

  • Zhejiang Provincial People's Hospital

    collaborator OTHER

  • First People's Hospital of Hangzhou

    collaborator OTHER

  • Second People's Hospital of Hangzhou

    collaborator UNKNOWN

  • The Third Affiliated hospital of Zhejiang Chinese Medical University

    collaborator OTHER

  • Ningbo People's Hospital

    collaborator UNKNOWN

  • Xiaoshan People's Hospital

    collaborator OTHER

  • Xiaoshan Hospital

    collaborator UNKNOWN

  • The First People's Hospital of Huzhou

    collaborator OTHER

  • Red Cross Hospital, Hangzhou, China

    lead OTHER

Principal Investigators

  • Chuang Cai, doctor · Red Cross Hospital, Hangzhou, China

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
30 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-10-31
Primary Completion
2016-10-31
Completion
2016-12-31

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02234739 on ClinicalTrials.gov